# **Financial Information**

### HORIBA, Ltd.

December, 2020

© 2020 HORIBA, Ltd. All rights reserved.

# Contents

# 2020 3Q (Jan.-Sep.) Results

# 2020 Forecast

Shareholder Return

# **Topics** -New product development for focused markets-

# Financial Data

# Contents

# 2020 3Q (Jan.-Sep.) Results 2020 Forecast Shareholder Return Topics -New product development for focused markets-

# Financial Data

# 2020 <u>3Q</u> (Jan.-Sep.) Results

(Billons of Yen)

Decreased in sales and profits due to a decline in sales all business segments except the semiconductor segment

	2019	2020	vs 2019	
	3Q Results (Jan-Sep)	3Q Results (Jan-Sep)	Changes	%
Sales	137.0	129.7	-7.2	-5%
Operating Profit	12.0	10.9	-1.0	-9%
0.P.%	8.8%	8.5%	-0.3p	
Ordinary Profit	11.5	10.7	-0.7	-7%
Net income attributable to Owners or Parent	8.4	7.5	-0.9	-11%
USD/JPY	109.12	107.55	-1.57	
EUR/JPY	122.62	120.93	-1.69	

# 2020 <u>3Q</u> (Jan.-Sep.) Results by Segment

(Billons of Yen)

	Sales				
	2019		2020		
	3Q Results (Jan-Sep)	3Q Results (Jan-Sep)	vs 2019	%	
Auto	52.0	41.6	-10.4	-20%	
P&E	13.8	12.7	-1.0	-8%	
Medical	18.7	15.2	-3.4	-18%	
Semi	33.5	41.7	+8.2	+24%	
Scientific	18.8	18.3	-0.4	-3%	
Total	137.0	129.7	-7.2	-5%	

	Operating Profit				
	2019	2019 2020			
	3Q Results (Jan-Sep)	3Q Results (Jan-Sep)	vs 2019	%	
Auto	2.7	-0.0	-2.8	-	
P&E	0.9	0.7	-0.2	-22%	
Medical	1.0	-0.4	-1.5	-	
Semi	7.4	9.8	+2.4	+33%	
Scientific	-0.2	0.8	+1.1	-	
Total	12.0	10.9	-1.0	-9%	

<Auto>

 Affected by stagnation of corporate activities owing to the spread of COVID-19. EMS/MCT\*: Delayed product shipment and acceptance.

<P&E>

Affected by stagnation of corporate activities owing to the spread of COVID-19

<Medical>

• The number of tests performed at hospitals decreased as the spread of COVID-19 led to a decrease in the number of patients who visit hospital

#### <Semi>

• In response to a recovery of semiconductor manufacturers' capital expenditures driven by an increase in demand for semiconductors.

<Scientific>

- Sluggish R&D investment by private companies and others due to the spread of COVID-19
- Solid demand for optical components for semiconductor production equipment manufacturers and life science purposes

# Contents

# ■2020 3Q (Jan.-Sep.) Results

# 2020 Forecast

# Shareholder Return

**Topics** -New product development for focused markets-

# Financial Data

# 2020 External Environment

Coporol	Economic activities have been resumed after lifting of restrictions but the future remains uncertain.
General	Negative impacts from macroeconomic trends, such as the results of the US presidential election and the US-China trade conflicts, are of concern.
Auto	Most likely to be affected from automobile-related manufacturers' revision and reduction of R&D investments. Possible delay in shipment and acceptance of products because of measures to restrict the movement of people and goods by various countries and regions.
P&E	Public utility projects are continuing, driven by economic measures, but investment by companies is sluggish.
	Falling crude oil prices may result in reduction in investment by the oil industry.
Medical	The number of patients who visit hospitals is projected to continue declining globally, due to the COVID-19 crisis.
	Demand for testing will recover in the medium- to long-term.
Semi	In response to an increase in demand for semiconductors associated with the expansion of telework and digital business, semiconductor manufacturer's capital expenditures have recovered.
Scientific	Demand for semiconductor-related measurement technologies is increasing, while demand in the pharmaceutical and life science sectors is solid.
	R&D investment by companies is slow due to the sluggish economic activity.

# 2020 Forecast

(Billons of yen)

In light of the progress achieved up to the third quarter of this year, revised operating profit and ordinary profit forecasts

	2019	20	)20	Char	nges
	Results	Previous Forecasts (as of Aug. 11)	Forecasts (as of Nov. 12)	vs 2019	VS Previous Forecasts
Sales	200.2	188.0	188.0	-12.2	-
Operating Profit	20.9	15.0	16.0	-4.9	+1.0
O.P.%	10.4%	8.0%	8.5%	-1.9p	+0.5p
Ordinary Profit	20.5	14.5	15.0	-5.5	+0.5
Net income attributable to Owners or Parent	15.4	10.5	10.5	-4.9	-
USD/JPY	109.03	107.00	107.00	-2.03	
EUR/JPY	122.03	120.00	120.00	-2.03	

(Billons of yen)

# 2020 Forecast by Segment

	Sales				
	2019		2020		
	Results	Previous Forecasts (as of Aug. 11)	Forecasts (as of Nov. 12)	vs 2019	vs Previous Forecasts
Auto	81.0	68.0	67.0	-14.0	-1.0
P&E	19.5	17.5	18.0	-1.5	+0.5
Medical	25.3	22.0	21.0	-4.3	-1.0
Semi	47.1	54.0	55.5	+8.3	+1.5
Scientific	27.1	26.5	26.5	-0.6	-
Total	200.2	188.0	188.0	-12.2	-

	Operating Profit				
	2019	2019 2020			
	Results	Previous Forecasts (as of Aug. 11)	Forecasts (as of Nov. 12)	vs 2019	vs Previous Forecasts
Auto	6.4	0.5	0.5	-5.9	-
P&E	1.6	0.5	1.0	-0.6	+0.5
Medical	1.3	-	-0.5	-1.8	-0.5
Semi	10.7	13.5	14.0	+3.2	+0.5
Scientific	0.7	0.5	1.0	+0.2	+0.5
Total	20.9	15.0	16.0	-4.9	+1.0

<Auto>

 Product shipment and acceptance expected to be delayed in EMS and MCT.

<Medical>

• The number of tests performed at hospitals is projected to continue to stagnate, along with an anticipated decrease in the number of patients who visit hospital.

#### <Semi>

• Revised upward due to a increase in sales in response to a increase demand for semiconductors

#### <P&E, Scientific>

• In light of the progress achieved up to the third quarter of this year, revised upward forecasts

# Contents

# 2020 3Q (Jan.-Sep.) Results2020 Forecast

# Shareholder Return

**Topics** -New product development for focused markets-

# Financial Data

# Shareholder Return

#### Dividends per share and Share buybacks

2018 Results 145yen [Interim 50yen/Year-end 95yem]

2019 Results 130yen [Interim 50yen/Year-end 80yen]

2020 Forecasts 75yen [Interim 30yen/Year-end 45yen]

(remains unchanged from disclosure on 9th June)

Ordinary dividend: <u>125yen</u> Commemorative dividend for the 65th anniversary of the company foundation: <u>20yen</u>

**Basic policy** 

Dividend payment + Share buyback = 30% of Consolidated net profit to be targeted
 Remaining earnings are retained internally for strategic investment (i.e. facilities, M&A)

# Contents

# 2020 3Q (Jan.-Sep.) Results 2020 Forecast Shareholder Return Topics -New product development for focused marketsFinancial Data

### New Product Development for Focused Markets

**MLMAP2023** 

**Market Oriented Business** 

**Bio & Healthcare/Materials & Semiconductor** 

[Three fields of focus by HORIBA]					
Market         Energy & Environment         Bio & Healthcare         Materials & Semiconductor					
Main TargetMobility, Power generation, Environmental preservation, WaterClinical testing, Pharmaceutical, Drug discovery, Cells, DNAAdvanced materials, Materials for semiconductor					
Mid-Long Term Management Plan "MLMAP2023" — Market Oriented Business					

#### Deploying new measurement and analysis solutions utilizing core technologies in focused markets

Development in the bio-markets, such as drug discovery and regenerative medicine

#### Optical Component "OC-300"

- The key component of the OCT<sup>\*</sup> system used for fundus examination in ophthalmology
- Imaging technology for shooting the internal structure and shape of a sample with highresolution, high-speed, and non-contacting.

\*Optical Coherence Tomography



Contributing to material development and quality control of semiconductors and secondary batteries

#### Centrifugal nanoparticle analyzer "Partica CENTRIFUGE"

- ✓ Particles contained in the sample can be measured at the nano-level.
- ✓ The condition of the material can be visualized.



# New Product Development for Focused Markets

MLMAP2023 Market Oriented Business Energy & Environment

#### Strengthening the existing areas and further challenging growth areas

#### Highly accurately reproduce complex Real Driving Emissions (RDE) in the lab

Significantly broader test conditions; more complex operating and environmental conditions

#### New application "RDE+"

- Developed an indoor measurement method that reproduces the same driving environment as outdoors.
- Obtain actual driving data, and reproduce it with a chassis dynamometer and a robot driver.



Up to 75%\* reduction in pototype vehicle production cost

Opened a safety test facility for in-vehicle batteries



Engaged in the development and testing of in-vehicle batteries for 20 years

Enables a composite environmental evaluation test of batteries

- $\checkmark\,$  Covers small, medium, and large batteries.
- During a vibration test, implement battery charge/discharge and temperature adjustment simultaneously.



Contributes to product development efficiency and cost reduction

\*Survey by US-based research and consulting firm Frost & Sullivan © 2020 HORIBA, Ltd. All rights reserved.

# Contents

# 2020 3Q (Jan.-Sep.) Results 2020 Forecast Shareholder Return Topics -New product development for focused markets-

### Financial Data

# Impact of Fluctuation in Foreign exchange

Exchange rate impact (2020 3Q results)

Sales -¥1.80bn O.P. -¥0.61bn


2020 3Q results	vs 2019 3Q
Decrease Sales	- 1.80
Decrease Cost of Goods Sales	+ 0.70
Decrease Expenses	+ 0.48
Impact to Operating Profit	- 0.61

(Yen)	2019 3Q	2020 3Q	Diff.
USD	109.12	107.55	-1.57
EUR	122.62	120.93	-1.69

Exchange rate impact for 2020 Forecast 1 yen impact of Sales and O.P. (Yen appreciation) Sales USD -¥0.48bn -¥0.30bn EUR **Operating Profit** USD -¥0.21bn EUR -¥0.01bn 2020 Forecast (Yen) USD 107.00 EUR 120.00

(Billions of yen)

# Operating Profit Analysis (vs 2019)



# Capital Investment, Depreciation, R&D

(Billions of yen)


	2019		2020	)		2019	2020
	Results	Forecasts (as of Aug. 11)	Forecasts (as of Nov. 12)	vs 2019	vs Previous Forecasts	Results (Jan Sep.)	Results (Jan Sep.)
Capital Investment	12.8	17.5	17.5	+4.6	-	8.3	9.8
Depreciation	8.7	9.5	9.5	+0.7	-	6.4	7.1
R&D	16.2	16.0	16.0	-0.2	-	12.2	11.6
(To Net Sales)	8.1%	8.5%	8.5%	+0.4p	-	9.0%	9.0%

#### -PP&E:

2020 Topics Enhance the base of service business, investment to HORIBA MIRA, HORIBA FuelCon's new facility, a new facility in China

Scrutinize urgency and priority and make investment decisions

(Consolidated basis) (Billions of yen)



• Recent issuer rating: R&I "A" (Sep. 2020), JCR "A+" (Aug. 2020)


Cash Balance

# Contents

# ■2020 3Q (Jan.-Sep.) Results ■2020 Forecast Shareholder Return **Topics** -New product development for focused markets-Financial Data


# **Business Segments**






# Expanding in New Domains and Moving onto a New Stage

# **Global Network**



# HORIBA's Steady Growth



# HORIBA MIRA Ltd. HORIBA BIWAKO E-HARBOR


# HORIBA MIRA Ltd.

Providing Engineering Service with World Leading Mobility Development Capability and R&D Location with Dedicated Facilities and Proving Ground

<b>Business Offering</b>	1. Vehicle development engineering
	2. Test engineering
	3. MIRA Technology Park
	(Providing Unique R&D Location)
Established	1946
Head office	Nuneaton, Warwickshire, UK
<b>Major locations</b>	U.K., China, and India



# **MIRA Technology Park**





# HORIBA BIWAKO E-HARBOR


- Consolidating development, design, and production operations of gas measurement equipment at a single location
- Doubling of production capability and shortening delivery time to one-third by using a new production methodology
- Comprehensive engineering services from sales to development, production, and maintenance in the Automotive testing laboratory
  - Profitability improvement of exhaust gas analyzers
  - Presenting cutting edge automotive development technology





Total investment: 10.0 billion yen, Location: Otsu City, Shiga Prefecture, Full operation : May 2016

# HORIBA BIWAKO E-HARBOR















# Thank you

